AtkinsonTMWagnerJSBaschE.Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials. JAMA Oncol2017; 3(6): 738–739.
2.
KluetzPGO’ConnorDJSoltysK.Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol2018; 19(5): e267–e274.
3.
King-KallismanisBLHowieLJRoydhouseJKet al. Patient reported outcomes in Anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. Clin Trials2019; 16(3) 322–326.
4.
BaschERogakLJDueckAC.Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther2016; 38(4): 821–830.
5.
TraskPCDueckACPiaultEet al. Patient-reported outcomes version of the common terminology criteria for adverse events: methods for item selection in industry-sponsored oncology clinical trials. Clin Trials2018; 15(6): 616–623.
6.
DeMuroCClarkMDowardLet al. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). Value Health2013; 16(8): 1150–1155.
RoydhouseJKKing-KallimanisBLHowieLJet al. Blinding and patient-reported outcome completion rates in US food and drug administration cancer trial submissions, 2007-2017. J Natl Cancer Inst. Epub ahead of print 17 December 2018. DOI: 10.1093/jnci/djy181.
9.
BaschE.High compliance rates with patient-reported outcomes in oncology trials submitted to the US food and drug administration. J Natl Cancer Inst. Epub ahead of print 17 December 2018. DOI: 10.1093/jnci/djy183.
